Positive effect of if-channel’s blocker ivabradine therapy in a patient with ischemic chronic heart failure with preserved left ventricle ejection fraction and hereditary thrombophilia (clinical case)


Chronic heart failure is one of the leading causes of mortality among patients with cardiovascular diseases. Current therapeutic methods for treating patients with chronic heart failure do not always provide a significant improvement in main intermediate and final outcomes. According to the neurohumoral theory of chronic heart failure development, an antagonism of the sympathoadrenal system with b-blockers is pathogenetically substantiated, and the drugs of this group are one of the first-line treatment for chronic heart failure. The selection of heart rate-reducing therapy in patients with chronic heart failure caused by ischemia, can often be difficult due to development of b-blockers side effects, b-blockers intolerance and/or due to the presence of contraindications at severe comorbid pathology. This article presents a clinical case of an effective administration of ivabradine, a drug of if-channel inhibitors group, in combination with b-blockers to a patient with chronic heart failure with a preserved ejection fraction.

Full Text

Restricted Access

About the authors

Iurii N. Belenkov

Sechenov First Moscow State Medical University (Sechenov University)

Moscow, Russia
Acad. RAS, D. Sci. (Med.), Prof

Elena V. Privalova

Sechenov First Moscow State Medical University (Sechenov University)

Moscow, Russia
D. Sci. (Med.), Prof.

Irina S. Ilgisonis

Sechenov First Moscow State Medical University (Sechenov University)

Moscow, Russia
Cand. Sci. (Med.)

Iuliia I. Naymann

Sechenov First Moscow State Medical University (Sechenov University)

Moscow, Russia
Cand. Sci. (Med.)

Alexey V. Zhito

Sechenov First Moscow State Medical University (Sechenov University)

Email: azhito77@mail.ru
Moscow, Russia
Graduate Student


  1. Kenworthy W, Guha K, Sharma R. The patient with left ventricular systolic dysfunction now and in the future. Br J Hosp Med (Lond) 2016; 77: 516-22. doi: 10.1177/2040622318784556
  2. Фомин И.В. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации - данные ЭПОХА-ХСН. Сердечная недостаточность. 2006; 7 (1): 112-5. https://doi.org/10.15829/ 1560-4071-2016-8-7-13 @@Fomin I.V. et al. Rasprostranennost' khronicheskoi serdechnoi nedostatochnosti v Evropeiskoi chasti Rossiiskoi Federatsii - dannye EPOKhA-KhSN. Serdechnaia nedostatochnost'. 2006;(1): 112-5. https://doi.org/10.15829/1560-4071-2016-8-7-13 (in Russian)
  3. Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА- О-ХСН). Сердечная недостаточность. 2004; 5 (1): 4-7. @@Ageev F.T., Danielian M.O., Mareev V.Iu. et al. Bol'nye s khronicheskoi serdechnoi nedostatochnost'iu v rossiiskoi ambulatornoi praktike: osobennosti kontingenta, diagnostiki i lecheniia (po materialam issledovaniia EPOKhA-O-KhSN). Serdechnaia nedostatochnost'. 2004; 5 (1): 4-7 (in Russian).]
  4. Мареев В.Ю., Даниелян М.О., Беленков Ю.Н. От имени рабочей группы исследования ЭПОХА-О-ХСН. Сравнительная характеристика больных с ХСН в зависимости от величины ФВ по результатам Российского многоцентрового исследования ЭПОХА-О-ХСН. Сердечная недостаточность. 2006;7 (4): 164-71. @@Mareev V.Iu., Danielian M.O., Belenkov Iu.N. Ot imeni rabochei gruppy issledovaniia EPOKhA-O-KhSN. Sravnitel'naia kharakteristika bol'nykh s KhSN v zavisimosti ot velichiny FV po rezul'tatam Rossiiskogo mnogotsentrovogo issledovaniia EPOKhA-O-KhSN. Serdechnaia nedostatochnost'. 2006;7 (4): 164-71 (in Russian).]
  5. EURObservational Research Programme: Regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Failure 2013; 15 (7). doi: 10.1093/eurjhf/hft050
  6. Mozzafarian D, Benjamin E.J, Go A.S et al. Heart disease and stroke statistics - 2016 update: a report from the American Heart Association. Circulation 2016; 133: e38-e360. https://doi.org/10.1161/CIR.0000000000000350
  7. National Institute for Health and Care Excellence. Chronic heart failure in adults: management, https://www.nice.org.uk/guidance/ cg108/resources/chronic-heart-failure-in-adultsmanagement-pdf-35109335688901 (2010, accessed 14 January 2018).
  8. Cook S, Togni M, Schaub M.C et al. High heart rate: a cardiovascular risk factor? Eur Heart J 2006; 27: 2387-93.
  9. Fox K, Borer J.S, Camm A.J et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823-30. https://doi.org/10.1016/j.jacc.2007.04.079
  10. Reil J.C, Bohm M. The role of heart rate in the development of cardiovascular disease. ClinRes Cardiol2007; 96: 585-92. doi: 10.1007/s00392-007-0537-5
  11. Lechat P, Hulot J.S, Escolano S et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103: 1428-33. https://doi.org/10.1161/01
  12. Flannery G, Gehrig-Mills R, Billah B et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008; 101: 865-69. doi: 10.1016/j.amjcard.2007.11.023
  13. McAlister F.A, Wiebe N, Ezekowitz J.A et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784-94. doi: 10.7326/0003-4819-150-11-200906020-00006
  14. Gloekler S, Traupe T, Stoller M et al. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. Seiler Heart 2014; 100 (2): 160-6. doi: 10.1136/heartjnl-2013-304880
  15. Lopatin Y.M, Vitale C. Effect of ivabradine on central aortic blood pressure in patients with stable coronary artery disease: What do we know? IntJ Cardiol 2016; 224: 145-8. doi: 10.1016/j.ijcard.2016.09.054
  16. Fox K, Ford I, Steg P.G et al. Ivabradine for patients with stable coronary artery disease and leftventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-16. doi: 10.1016/S0140-6736(08)61170-8
  17. Tardif J-C, Ponikowski P, Kahan T on behalf of the ASSOCIATE investigators. Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol 2013; 168; 789-94. http://dx.doi.org/10.1016/j.ijcard.2012.10.011
  18. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875-85. doi: 10.1016/S0140-6736(10)61198-1
  19. Ponikowski P, Voors A.A, Anker S.D et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18 (8): 891-975. doi: 10.1002/ejhf.592



Abstract - 7

PDF (Russian) - 0


Article Metrics

Metrics Loading ...




  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies